Search Results for "gestodene"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for gestodene. Results 1 to 6 of 6 total matches.

Desogestrel - A New Progestin for Oral Contraception

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993  (Issue 902)
new progestins (norgestimate and gestodene are the others) considered less androgenic than previously ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
Med Lett Drugs Ther. 1993 Aug 6;35(902):73-4 |  Show IntroductionHide Introduction

Combination Oral Contraceptives and the Risk of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010  (Issue 1334)
progestins desogestrel (e.g. Ortho-Cept, Kariva) or gestodene (not available in the US) compared to those ...
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing dysfunctional uterine bleeding and increasing serum hemoglobin concentrations. Are these benefits worth the risk? And are some combination oral contraceptives safer than others?
Med Lett Drugs Ther. 2010 Mar 22;52(1334):23-4 |  Show IntroductionHide Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
used in combination OCs (desogestrel and, outside the US, gestodene) have been associated ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 |  Show IntroductionHide Introduction

Topical Roflumilast (Zoryve) for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
and the synthetic progestin gestodene increased systemic exposure of oral roflumilast. DOSAGE AND ADMINISTRATION ...
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa), another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-2   doi:10.58347/tml.2023.1668b |  Show IntroductionHide Introduction

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024  (Issue 1700)
In a pharmacokinetic study, coadministration of ethinyl estradiol and the synthetic progestin gestodene increased ...
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation (Daliresp, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9   doi:10.58347/tml.2024.1700a |  Show IntroductionHide Introduction

Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
, norgestimate or, outside the USA, gestodene) used in combination oral contraceptives have been claimed ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Med Lett Drugs Ther. 2000 May 15;42(1078):42-4 |  Show IntroductionHide Introduction